171 related articles for article (PubMed ID: 37707759)
1. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.
Ouyang J; Yang Y; Zhou Y; Ye F; Wang Z; Li Q; Xu Y; Li L; Zhao X; Zhang W; Zhou A; Huang Z; Wang Y; Cai J; Zhao H; Zhou J
Hepatol Int; 2023 Dec; 17(6):1519-1531. PubMed ID: 37707759
[TBL] [Abstract][Full Text] [Related]
2. The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.
Yang Y; Li L; Xu Y; Ouyang J; Zhou Y; Ye F; Huang Z; Zhang W; Zhou A; Zhao X; Cai J; Wang Y; Zhou J; Zhao H
Radiol Med; 2024 Feb; 129(2):188-201. PubMed ID: 38180570
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
4. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract][Full Text] [Related]
6. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
[TBL] [Abstract][Full Text] [Related]
8. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Guan R; Mei J; Lin W; Deng M; Li S; Guo R
Hepatol Int; 2023 Oct; 17(5):1279-1288. PubMed ID: 37129721
[TBL] [Abstract][Full Text] [Related]
9. Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy.
Hu ZX; Xu XY; Wang Z; Huang JT; Li WC; Zhang S; Shen J; Zhong BY; Zhu XL
J Hepatocell Carcinoma; 2023; 10():2073-2082. PubMed ID: 38022730
[TBL] [Abstract][Full Text] [Related]
10. Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.
Hsu WF; Lai HC; Chen CK; Wang HW; Chuang PH; Tsai MH; Chen SH; Chu CS; Su WP; Chou JW; Kao JT; Chen HY; Chuang SC; Tsai TY; Hsiao WD; Huang GT; Peng CY
Am J Cancer Res; 2023; 13(2):654-668. PubMed ID: 36895987
[TBL] [Abstract][Full Text] [Related]
11. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.
Yang M; Pan Y; Wang W
BMC Cancer; 2023 Mar; 23(1):236. PubMed ID: 36915049
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.
Guo DZ; Zhang SY; Dong SY; Yan JY; Wang YP; Cao Y; Rao SX; Fan J; Yang XR; Huang A; Zhou J
Front Immunol; 2023; 14():1141199. PubMed ID: 36911686
[TBL] [Abstract][Full Text] [Related]
14. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.
Zhang XP; Wang K; Wei XB; Li LQ; Sun HC; Wen TF; Chai ZT; Chen ZH; Shi J; Guo WX; Xie D; Cong WM; Wu MC; Lau WY; Cheng SQ
Oncologist; 2019 Dec; 24(12):e1476-e1488. PubMed ID: 31138726
[TBL] [Abstract][Full Text] [Related]
15. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
16. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.
Li S; Wu J; Wu J; Fu Y; Zeng Z; Li Y; Li H; Liao W; Yan M
Front Immunol; 2023; 14():1109771. PubMed ID: 36875116
[TBL] [Abstract][Full Text] [Related]
17. Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study.
Lui TKL; Cheung KS; Leung WK
Hepatol Int; 2022 Aug; 16(4):879-891. PubMed ID: 35779202
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.
Wei H; Fu F; Jiang H; Wu Y; Qin Y; Wei H; Yang T; Wang M; Song B
Eur Radiol; 2023 Nov; 33(11):7631-7645. PubMed ID: 37191923
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
[TBL] [Abstract][Full Text] [Related]
20. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
